Jeanmarie Guenot, PhD. has an experience of over 20 years in biotechnology and pharmaceutical of life industry give her quite a broad expertise in the health sector. She earned PhD. from University of California and MBA from Wharton School. Through her career life, she has worked in both private and public sector in all stages. Her career in business started at Atlas Venture where he built companies dealing with life science. She trained in medicinal and physical chemistry focusing on semi-empirical and quantum methods for drug design, X-ray and NMR, molecular dynamics and protein structure prediction on guenotllc.com. On the other hand, her career in science started as a scientist principal in Preclinical R&D where she discovered and developed drugs to deal with metabolic diseases, autoimmune diseases, inflammation, and oncology. As the vice president of Business and Corporate at PDL BioPharma she was leading alliance management, acquisitions and mergers, licensing as well as commercial product portfolios which made the corporate and business department to grow rapidly. Jeanmarie Guenot also led the negotiation of Biogen Idec-PDL co-commercialization collaboration and co-development which involved autoimmune disease and two cancer drug candidates’ phase. On the other hand, she has experience in alliance management, portfolio, and project.
JeanMarie Guenot is the current CEO and President of Amphivena Therapeutics, a preclinical stage company which has accomplished a lot in developing innovative antibody therapies to deal with hematologic malignancies. In her current position and role as the CEO and president, she has founded SKS Ocular which is a start-up ophthalmic incubator focusing on AMD, glaucoma therapeutics, ocular inflammation, muscular degeneration and technological delivery of ocular drug where she acted as the key and chief operation officer.
Under her leadership, Amphivena entered an agreement that gives Janssen exclusive right to acquire Amphivena through IND approval on amphivena.com. Janssen role was to provide first upfront payment and the additional contingent fee which is based on reaching on a predetermined achievement in return for the agreement. She announced how delighted the company was, to have achieved their goal much earlier and is looking forward to developing and advance therapeutic candidate so as to address the need for individuals suffering from cancer in the clinic.